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Abstract 
Background: A key component of schistosomiasis control is mass drug administration with praziquantel. While con-
trol interventions have been successful in several endemic regions, mass drug administration has been less effective 
in others. Here we focus on the impact of repeated praziquantel treatment on the population structure and genetic 
diversity of Schistosoma mansoni.
Methods: We examined S. mansoni epidemiology, population genetics, and variation in praziquantel susceptibility in 
parasites isolated from children across three primary schools in a high endemicity region at the onset of the Ugandan 
National Control Programme. Children were sampled at 11 timepoints over two years, including one week and four 
weeks post-praziquantel treatment to evaluate short-term impacts on clearance and evidence of natural variation in 
susceptibility to praziquantel.
Results: Prevalence of S. mansoni was 85% at baseline. A total of 3576 miracidia larval parasites, isolated from 203 
individual children, were genotyped at seven loci. Overall, genetic diversity was high and there was low genetic dif-
ferentiation, indicating high rates of parasite gene flow. Schistosome siblings were found both pre-treatment and four 
weeks post-treatment, demonstrating adult worms surviving treatment and natural praziquantel susceptibility varia-
tion in these populations at the beginning of mass drug administration. However, we did not find evidence for selec-
tion on these parasites. While genetic diversity decreased in the short-term (four weeks post-treatment), diversity did 
not decrease over the entire period despite four rounds of mass treatment. Furthermore, within-host genetic diversity 
was affected by host age, host sex, infection intensity and recent praziquantel treatment.
Conclusions: Our findings suggest that praziquantel treatments have short-term impacts on these parasite popu-
lations but impacts were transient and no long-term reduction in genetic diversity was observed. High gene flow 
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Background
Schistosomiasis is a neglected tropical disease that infects 
over 240 million people across 78 countries, predomi-
nantly within the developing world [1]. Adult Schisto-
soma mansoni sexually reproduces (predominantly) in 
humans and eggs are excreted in faeces. In high ende-
micity areas, worm burdens can be very heavy, produc-
ing as many as 9600 eggs per gram (epg) of stool [2]. In 
areas with inadequate containment of stool due to poor 
sanitation, eggs contact freshwater and hatch into free-
swimming miracidia. Miracidia then infect suitable snail 
intermediate hosts and undergo asexual reproduction, 
releasing thousands of free-swimming clonal cercariae 
daily [3]. Cercariae burrow through the skin to infect 
humans when they contact infectious water, through 
activities such as bathing, gathering water or fishing. 
Despite the integral role of insufficient water, sanita-
tion and hygiene (WASH) in maintaining transmission, 
preventative chemotherapy through mass drug admin-
istration (MDA) with praziquantel is currently the main 
strategy for controlling morbidity, and ultimately trans-
mission, of schistosomiasis in endemic areas [4]. While 
MDA has been successful in reducing morbidity and 
prevalence or intensity of schistosomiasis across many 
parts of sub-Saharan Africa [5–7], persistent transmis-
sion hotspots of Schistosoma species remain [8, 9].
Studies investigating the genetic structure of Schisto-
soma populations and their response to MDAs have the 
ability to quantify the impact and potential limitations 
of MDAs [10, 11]. These findings could help identify 
parasite-specific characteristics contributing to persis-
tent transmission. The impact of treatment on parasite 
populations depends on many factors including, but not 
exclusive to, population coverage, frequency of drug 
pressure, baseline levels of parasite genetic diversity [12, 
13], and rates of parasite gene flow [14]. Drug selec-
tion has been linked to lower effective population sizes 
[15] and can reduce genetic diversity of parasites in the 
laboratory [16]. In the field, treatment generally reduces 
prevalence and intensity of parasites in targeted popula-
tions and individuals [17, 18], but can also measurably 
reduce transmission rates across the population, influ-
encing infections in individuals beyond the treated group 
[19–21]. However, treatments can also select for reduced 
drug efficacy and/or increase in resistance in populations 
[22–25]. Therefore, it is important to understand how 
parasites are structured across the landscape, and within 
individuals, in order to monitor treatment impacts and 
manage for the potential emergence and spread of drug 
resistance.
Several studies in Africa support a lack of genetic popu-
lation structure in Schistosoma species at relatively small 
scales, from within villages to between sites up to 60 km 
apart [26–30]. High rates of gene flow suggest there are 
minimal barriers for transmission, at least at these geo-
graphical scales. The only large-scale study to date, to 
the authors’ knowledge, which encompassed five African 
countries, also found little support for structure between 
geographically close sites but distinct parasite clusters at 
the country level [31]. However, in some parts of Brazil, 
gene flow has been observed to be limited, even between 
sites 6 km apart [32]. Human movement patterns and 
water flow have also been shown to facilitate parasite 
population structure between different boroughs within a 
single town [33]. Higher overall levels of genetic diversity 
and longer history of transmission of S. mansoni in East 
Africa relative to South America may contribute to these 
differences in population structure, but studies explicitly 
evaluating these hypotheses are lacking.
At least under laboratory conditions, praziquantel 
reduces the diversity of S. mansoni and drug resistance 
can be selected for in as few as six generations [34, 35]. 
Reduced drug efficacy has also been recorded in sev-
eral endemic areas, including Uganda [24, 36], though 
the geographic spread of resistance has not yet been 
documented. There are no genetic markers for resist-
ance or reduced susceptibility to praziquantel in any 
schistosomes and the mechanism of action for the drug 
is unknown, complicating understanding treatment fail-
ures. The effect of praziquantel treatment on S. man-
soni genetic diversity in the field also offers conflicting 
results. Reduction of genetic diversity has been observed 
six months after a single praziquantel treatment in two 
schools in Tanzania [21, 37]. In contrast, studies in 
Kenya showed school-based praziquantel MDA did not 
reduce genetic diversity over a five-year period [2] and 
another study in Senegal showed no reduction in genetic 
diversity over two years [30]. Similarly, a study in Brazil 
reduces the likelihood of local adaptation, so even though parasites surviving treatment were observed, these were 
likely to be diluted at the beginning of the Ugandan National Control Programme. Together, these results suggest that 
MDA in isolation may be insufficient to reduce schistosome populations in regions with high genetic diversity and 
gene flow.
Keywords: Schistosomiasis, Mass drug administration, Praziquantel, Trematodes, Population genetics, Interventions, 
Natural variation
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demonstrated little differentiation between parasites iso-
lated pre-treatment and four to six weeks post-treatment 
[38].
Here we focus on the structure and genetic diversity 
of S. mansoni at the beginning of the MDA in Uganda, 
the first schistosomiasis MDA programme in sub-Saha-
ran Africa [39]. Few field studies to date have examined 
Schistosoma genetic diversity over short (less than one 
month) and medium-term (six months or more) follow-
ups after praziquantel treatment. In this study, we use a 
unique longitudinal dataset to examine how repeated 
praziquantel treatments can affect schistosome popula-
tions. We examine evidence for adult worms surviving 
treatment, suggesting natural variation in tolerance or 
resistance to praziquantel treatment. We hypothesize 
that mean genetic diversity would decline immediately 
following praziquantel treatment but expect diversity to 
recover at longer time-scales because of high gene flow 
and high genetic diversity at the population level. We 
expect clearance of parasites to be high, as host popu-
lations were praziquantel-naïve and parasites had not 
undergone repeated rounds of praziquantel selection.
Methods
Parasite sampling
Children aged 6–12 years were initially recruited for this 
study in 2004 with an equal sex ratio from three primary 
schools on the shores of Lake Victoria in eastern Uganda 
(Fig. 1a, b). The primary schools are located in three sep-
arate villages within Mayuge District and between 4.35 
km and 18.75 km apart (road and shoreline distances; as 
a proxy for actual travel distances are greater; Additional 
file 1: Table S1). Sample recruitment has been described 
previously [40, 41] and full details of new recruits and 
follow-ups are given in Additional file  1: Text S1 and 
Table  S2. After the initial recruitment, an additional 30 
praziquantel-naïve 6-year olds were recruited each year 
and included in follow-up surveys. Across a two-year 
period, there were a total of 11 sampling timepoints 
(Fig. 1c). Sample timepoints were designed to capture the 
effect of praziquantel treatment on parasite epidemiology 
and genetics in the short-term (one week and four weeks 
post-treatment) and medium-term (six months or more 
post-treatment). We acknowledge that medium-term is 
not reflective of an absolute definition but is used within 
this manuscript for convenience to describe discrete 
sampling windows.
At each timepoint, stool samples were collected for 
three consecutive days to measure infection intensity 
by duplicate Kato-Katz thick smears [42]. The number 
of S. mansoni eggs observed in a slide was multiplied 
by 24 to obtain eggs per gram (epg) (a standard 41.2 
mg template was used to prepare). After Kato-Katz 
slides were prepared, the remainder of each stool sam-
ple was filtered through a Pitchford funnel to collect 
and hatch miracidia from eggs [43]. Filtered samples 
were exposed to sunlight and individual miracidia were 
picked up in 2.5–5.0 μl bottled spring water under 
a stereomicroscope. In 2004, single miracidia were 
placed in individual PCR tubes and kept cool until 
flash freezing each evening in a − 80  °C freezer and 
then shipped on dry ice to Imperial College London. 
From 2005 onwards, individual miracidia were placed 
on Whatman Indicating  FTATM cards for cell lysis 
and DNA storage [44]. Cards were kept at room tem-
perature in sealed plastic bags with desiccants in the 
field and during transport. As many miracidia as pos-
sible were collected for each child onto a single FTA 
card per timepoint resulting in a final range of 0–132 
miracidia collected per child at any given timepoint. 
We use previous nomenclature and define all parasites 
isolated from a single child as an infrapopulation [37]. 
The cumulative number of miracidia at each timepoint 
is given in Fig. 1c.
The entire cohort was treated with praziquantel after 
each medium-term timepoint (no praziquantel treatment 
in the previous four weeks), indicated by red arrows in 
Figs. 1c and 2. At week 1, children with infection intensi-
ties greater than 100 epg were retreated with praziquan-
tel. At all other timepoints, children were retreated with 
praziquantel if they had any S. mansoni eggs detected in 
any Kato-Katz slides. Children were treated with 40 mg/
kg praziquantel, determined by weight. At all timepoints, 
observed treatment was recorded for each child.
A randomly selected subset of miracidia from 11 chil-
dren at 26 and 27 weeks were used for an in vitro assay 
that measured phenotypic praziquantel susceptibility of 
miracidia. This in vitro assay exposes miracidia to prazi-
quantel and uses changes in shape, behaviour and activity 
levels as a proxy for susceptibility and has been validated 
in prior laboratory and field studies [40, 45]. Here we 
have linked key summary measures for each infrapopu-
lation to genetic data from these corresponding hosts. 
Two measures that showed the most variation between 
individuals (but not among) were used as a proxy for 
praziquantel susceptibility of miracidia: the proportion 
of miracidia that had abnormal movement and the pro-
portion of miracidia that were immobile/dead after seven 
minutes in vitro exposure to 2 × 10−6 M praziquantel. 
Resistant genotypes have fewer changes in shape and 
behavioural responses to praziquantel exposure and thus 
a higher proportion of these miracidia are still behaving 
normally at seven minutes [40, 45]. Because individual 
miracidia were not simultaneously phenotyped and geno-
typed, average metrics for infrapopulations at each time-
point were linked.
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Laboratory analyses
DNA extraction and microsatellite analysis followed 
established protocols [44]. Briefly, individual miracidia 
were sized at seven microsatellite loci (Additional file 1: 
Table  S3) in a single multiplex reaction that have low 
error rates in S. mansoni from Lake Albert, Uganda. 
Allele sizes were determined using ABI PRISM Genescan 
v2.7 and Genotyper v2.7 software (Applied Biosystems, 
Foster City, CA, USA).
While we aimed to amplify all microsatellites from 30 
miracidia per infrapopulation per timepoint, one quarter 
of timepoints were represented by fewer than ten mira-
cidia. This disparity in terms of sample size could affect 
the statistical power of the models and the accuracy of 
genetic diversity measures. However, a simulation study 
using similar microsatellite markers reported that more 
robust measures of genetic diversity are obtained when 
increasing the number of hosts rather than the number 
of miracidia per host [37]. Additional limitations of this 
study include genotypic errors inherent in these micro-
satellite markers [44] that may affect the conclusions. 
However, we were very stringent with allele calls and 
inclusion criteria to minimize these biases.
Data analyses
All analyses were carried out in R v3.5.1 [46]. Specific 
packages are cited alongside functions used and sum-
mary code for these analyses can be found on github (see 
section “Availability of data and materials” below).
Epidemiological summary statistics
Individual schistosome infection intensities were calcu-
lated as an arithmetic mean of epg estimates from daily 
Kato-Katz slides examined at that timepoint. Paired rank 
a
c
b
Fig. 1 Sampling locations and timeline of genetic samples. a Map of Uganda with b Mayuge district (dark red) and the three primary schools 
[Bugoto Lake View (Bugoto-orange), Bwondha (Bwondha-yellow) and Musubi Church of God (Musubi-teal)] indicated and the number of miracidia 
sampled at each timepoint (c). The red arrows indicate praziquantel given to the entire cohort after medium-term schistosomiasis surveys
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sum Wilcoxon tests were used to test differences between 
pre- and post-treatment infection intensities. Popula-
tion prevalence was calculated at each timepoint for each 
school and 95% confidence intervals (CI) intervals were 
calculated with Agresti-Coull approximations [47].
Genetic diversity measures
Departure from Hardy–Weinberg equilibrium (HWE) 
was quantified in pegas v0.11 [48], implementing the 
Monte Carlo procedure present in the function hw.test 
with 1000 permutations. At each sampling point, infrap-
opulation schistosome diversity observed heterozygosity 
 (Ho) and expected heterozygosity  (He) were calculated in 
poppr v2.8.1 [49]. Allelic richness (AR), which corrects 
the number of alleles per locus for uneven sample size, 
was calculated for each infrapopulation and timepoint 
using the hierfstat package v0.04-22 [50].
Determining spatial, temporal and host effects 
on infrapopulation genetic diversity
To identify potential factors that affected the observed 
infrapopulation genetic diversity of parasites at a 
given timepoint, we constructed linear models using 
the function lm. Child ID (unique value identifying 
individual) was included as a random effect in a lin-
ear mixed effect model using lme4 [51] to account for 
repeated samples from the same infrapopulation over 
time, but was found to be insignificant. Explanatory 
variables included age, sex of child, cumulative num-
ber of observed praziquantel treatments, time since last 
observed treatment (in weeks), infection intensity at 
that sampling timepoint, and weeks from the beginning 
of MDA in that community. Sampling timepoints were 
also divided into three distinct categories: pre-treat-
ment (weeks 0, 26, 52, 104); one week post-treatment 
a
b
c
Fig. 2 Epidemiology and genetic diversity of S. mansoni in Mayuge District from 2004–2006. Prevalence of S. mansoni infection (a) and mean 
infection intensity, as eggs per gram of stool (epg) (b), estimated with three days of replicate Kato-Katz in each of the three schools sampled. Red 
arrows indicate timing of mass praziquantel treatment. c The mean allelic richness for all infrapopulations sampled at each timepoint for each 
school. No miracidia were isolated from infrapopulations in Bwondha at week 56
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(weeks 1, 27, 53, 58); and four weeks post-treatment 
(weeks 4, 56, 108). This was performed to increase 
statistical power, as post-treatment, especially at four 
weeks post-treatment, fewer miracidia were collected. 
The number of miracidia per infrapopulation per time-
point was included in the models as weights to reduce 
bias associated with estimates based on smaller sample 
sizes. Model comparison and selection was conducted 
using Akaike’s information criterion (AIC) [52].
Within‑host dynamics
Some infrapopulations were sampled for miracidia at 
more than one timepoint. To further examine within-
host dynamics, the genetic dataset was subset to include 
infrapopulations that were sampled at more than one 
timepoint, particularly pre-treatment and one week and 
four weeks post-treatment. Trees of infrapopulations 
over time were constructed using Nei’s distances in poppr 
v2.8.1 [49]. COLONY software was used to identify full-
sibling pairs between miracidia within infrapopulations 
using the full likelihood method and long runs [53]. 
Because only seven microsatellite loci are used, the abil-
ity to detect half-siblings amongst this dataset was very 
limited and therefore the mating system was assumed 
to be monogamous. Miracidia with ≥ 0.75 probability of 
belonging to a family were included in the analysis (< 0.75 
probability were assumed to be singletons). Our inter-
est was to identify the occurrence of siblings between 
pre- and post-treatment sampling points, suggesting 
adult worms surviving treatment and reproducing viable 
offspring.
Quantifying population structure and gene flow
To determine the levels of gene flow, we used several 
methods to quantify structure of populations. Analysis 
of molecular variance (AMOVA), which detects popu-
lation differentiation, was conducted using the func-
tion amova in poppr [49]. An AMOVA was carried out 
on the entire dataset to measure the genetic differentia-
tion between schools, among children between schools 
and within children. AMOVAs were also carried out 
at each timepoint. P-values were calculated by 1000 
random permutations. Population structure was also 
investigated using the discriminant analysis of princi-
pal components (DAPC) method [54] implemented in 
adegenet v2.1.1 [55], and by visualising Cavalli-Sforza & 
Edwards chord distances in hierfstat v0.04-22 with the 
neighbour-joining method implemented in ape v5.2 [56]. 
Phylogenetic trees were created using in vitro praziquan-
tel data to elucidate whether infrapopulations with more 
drug-resistant phenotypes at that timepoint were geneti-
cally distinct from those infrapopulations which were 
more susceptible.
Results
A total of 468 unique children were sampled for S. 
mansoni over 11 timepoints during the two-year study 
(Additional file 1: Table S2). Miracidia were isolated and 
analysed from 207 of these children from at least one 
timepoint. Deviations from Hardy–Weinberg equilib-
rium (HWE) were tested on the whole dataset of 4743 
miracidia. The majority of infrapopulations at each time-
point were found to strongly deviate from HWE. We 
then excluded miracidia that were not genotyped at all 
seven microsatellite loci, leaving a total dataset of 3576 
from 203 children (Fig. 1c). Despite a smaller total sample 
size, this subset showed little deviation from HWE and 
only four children were removed from the genetic analy-
ses. The number of miracidia successfully genotyped at 
seven loci within an infrapopulation ranged from 1 to 94 
per timepoint (mean 25.3).
Baseline S. mansoni infections and genetic diversity
Schistosoma mansoni was found in 85.7% of individu-
als surveyed at the beginning of the study, indicating a 
high endemic transmission setting (Fig. 2a). The average 
infection intensity within an individual at the beginning 
of the study was 224.9 epg (moderate infection inten-
sity; Fig.  2b). Genetic diversity of infrapopulations was 
also very high (Fig.  2c): average gene diversity among 
the loci (Hs) was 0.701 (range 0.280–0.888), while gene 
diversity among all populations (Ht) was 0.711 (range 
0.282–0.901) (Additional file  1: Table  S4). The number 
of alleles per locus ranged from 20 to 48. This supports 
the hypothesis that genetic diversity is high within these 
populations of S. mansoni.
Effect of praziquantel treatment on S. mansoni
One week post-treatment, genetic diversity was not 
significantly different than pre-treatment. This was 
also reflected in some of the epidemiological data; at a 
majority of time points and schools, the prevalence and 
infection intensity at one week post-treatment were not 
significantly different to pre-treatment (Additional file 1: 
Tables S5, S6).
However, prevalence and mean infection intensity 
significantly decreased at every four weeks post-treat-
ment observation compared to pre-treatment (Fig.  2a, 
Additional file  1: Tables S5, S6). These data indicate a 
high level of success by praziquantel in reducing egg 
output four weeks after treatment and suggest there 
should be high levels of selection imposed on the para-
sites in treated infrapopulations. Concurrent to these 
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epidemiological metrics, mean infrapopulation genetic 
diversity also significantly declined four weeks after each 
of the cohort treatments when accounting for age and 
sex of hosts (Fig.  3). This supports the hypothesis that 
praziquantel treatment reduces genetic diversity within 
treated individuals in the short-term following treatment.
Although these short-term effects were significant, 
prevalence, intensity and genetic diversity recovered over 
timescales greater than four weeks. Genetic diversity 
declined from baseline (week 0) to subsequent pre-treat-
ment samples (six months, one year and two years), but 
this decline was not significant (P > 0.05). This supports 
the hypothesis that genetic diversity of S. mansoni is 
resilient to praziquantel, at least within this observation 
period and setting.
Impact of treatment and host characteristics on S. mansoni 
infrapopulation genetic diversity
The best-fit model to explain infrapopulation genetic 
diversity, measured by AR at a given timepoint, contained 
infection intensity, short-term treatment, and an interac-
tion between age and sex as significant predictor variables 
(Fig. 4). The mean AR of an infrapopulation for a female 
host pre-treatment, also the intercept in this model, was 
1.65 (95% confidence interval (CI): 1.59  to  1.70). Each 
week post-treatment (up to four weeks), infrapopulation 
genetic diversity decreased (− 0.007, 95% CI: − 0.018 to 
− 0.001). Higher infection intensities slightly, but signifi-
cantly, had higher genetic diversity; each additional 100 
epg increased the mean allelic richness by 0.001 (95% CI: 
0.0004 to 0.0020). Infrapopulations of males had a higher 
genetic diversity than those of females (0.07; 95% CI: 0.01 
to 0.14). Schistosoma mansoni genetic diversity in female 
hosts increased with age (0.008; 95% CI: 0.002 to 0.015); 
however, in male hosts the interaction between age and 
sex reduced genetic diversity (− 0.010; 95% CI: − 0.018 to 
− 0.003).
Parasite structure and survival following treatment
Trees obtained from the Cavalli-Sforza & Edwards chord 
distances showed no clear clustering of infrapopula-
tions between timepoints, suggesting no selection on 
these markers imposed by praziquantel treatment in the 
observed timeframe. Parasites excreted four weeks post-
treatment were not more similar to one another com-
pared with parasites collected pre-treatment within the 
same year and across all timepoints (Additional file  1: 
Figure S1). Additionally, infrapopulations with higher 
levels of in vitro drug-resistant phenotypes were not 
genetically distinct from infrapopulations with lower 
measures of drug-resistant phenotypes (Additional file 1: 
Table S7, Figure S2).
Miracidia that were collected from six infrapopula-
tions before and after treatment showed evidence for 
clustering of pre-treatment and one week post-treat-
ment (Fig. 5, Additional file 1: Figure S3). Parasites four 
weeks post-treatment were more distant, even com-
pared to parasites sampled pre-treatment a year apart. 
We used COLONY to detect full siblings within these 
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infrapopulations sampled both pre- and post-treatment. 
Analysis of miracidia from these infrapopulations identi-
fied siblings between pre- and post-treatment sampling 
points (Fig.  6), suggesting adult worm pairs survived 
treatment and produced viable miracidia, particularly 
when siblings were found four weeks post-treatment. 
There was a higher proportion of siblings detected at 
one week post-treatment compared to four weeks post-
treatment, which was supported by phylogenies by time-
point (Fig. 5), but this is confounded by lower numbers 
of miracidia recovered four weeks post-treatment. Full 
siblings were found up to one year apart and following 
praziquantel treatment (Additional file 1: Tables S8, S9), 
but the number of miracidia recovered over longer time-
scales is very limited.
Gene flow between populations
The results of the AMOVA suggest a lack of structure 
between schools at different time points, showing that 
most of the variance in the dataset was explained by dif-
ferences within hosts. Mean percentage of variation was 
98.1% within hosts, 1.6% among hosts within schools 
and 0.3% between schools (Additional file 1: Table S10). 
 FST was lower between schools, ranging from − 0.007 to 
0.047, in the middle within schools, from 0.013 to 0.042 
and higher within hosts, ranging from 0.015 to 0.088 
(Additional file 1: Figure S4). The tree obtained from the 
Cavalli-Sforza & Edwards chord distances showed no 
clear clustering between villages (Additional file 1: Figure 
S5). Clustering algorithms implemented in DAPC also 
failed to identify an informative number of clusters in 
relation to school or timepoint (Additional file 1: Figure 
S6). These results support the hypothesis that gene flow 
is high between these populations.
Discussion
Using longitudinal epidemiological and genetic data from 
the start of MDA in Uganda, we show there are short-
term effects of praziquantel treatment on S. mansoni 
but populations recover within six months. Although we 
identify parasites surviving treatment even at the begin-
ning of MDA, there is no evidence that these parasites 
are selected for over this two-year period. High rates of 
gene flow between populations and refugia in snails and 
untreated individuals likely facilitate rapid recovery of 
parasite genetic diversity and prevent fixation of resist-
ant/tolerant parasites.
Cure rates during this study were within praziquan-
tel expectations at a population level for S. mansoni 
[57], suggesting that resistant/tolerant parasites are not 
overabundant in these study populations. However, we 
observed adult worms surviving treatment, as evidenced 
by full siblings found pre- and four weeks post-treatment 
a
b
Fig. 5 Phylogenies of infrapopulations from individual children 
sampled over time. The bootstrap support for each node is given and 
tips are labelled as the sampling time point. a A praziquantel naïve 6 
year-old recruited in 2005 (52 weeks) in Musubi and followed-up at 
each time point afterwards. b A praziquantel naïve 6 year-old in 2005 
(52 weeks) in Musubi that was followed at two post-treatment time 
point
Fig. 6 Histograms of family structure of full-siblings from six 
infrapopulations sampled pre-treatment, one week post-treatment 
and four weeks post-treatment. The distribution of miracidia from 
reconstructed maximum likelihood families are shown in the 
histogram. The majority of miracidia are from single families or 
families from the same timepoint; however, some full siblings are 
found between pre- and post-treatment, with the highest frequency 
between pre-treatment and one week post-treatment
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in four of six infrapopulations with sufficient sampling 
frequency. We believe these are resistant or tolerant 
adult worms and are likely a subset of the natural vari-
ation (rather than a result of selection). Infrapopulation 
genetic diversity was significantly lower at four weeks 
post-treatment, supporting this idea. Juveniles at point of 
treatment could be contributing to some eggs observed 
at four weeks post-treatment, but the presence of siblings 
pre- and four weeks post-treatment suggest that at least 
some eggs are from adult worms that survive praziquan-
tel. We also observed variation in phenotypic praziquan-
tel susceptibility, but we did not directly sequence these 
parasites. The phenotypic and genetic data from this set-
ting suggest that natural variation in this schistosome 
population has some praziquantel resistance or tolerance 
(we could not differentiate these with our data). This is 
consistent with evidence of natural variation in resist-
ance within schistosomes predating drug use to a former 
anti-schistosomal drug, oxaminiquine, where resistance 
alleles are known [58].
Despite evidence of resistant/tolerant parasites in this 
population, there was no evidence for selection for these 
parasites in the timeframe observed. Parasites found 
four weeks after treatment did not cluster, nor did phe-
notypically resistant parasite populations. High rates of 
transmission and high rates of gene flow likely prevent 
population bottlenecking and could reduce the likeli-
hood of resistance developing at a local level at the cover-
age levels and short- to medium- (under two years) time 
scales studied here [59]. Our genetic markers are likely 
not reflective of resistance; these microsatellite markers 
do not map to population (our study) or individual phe-
notypes [60]. It is not expected that microsatellites would 
be accurate markers for resistance, unless they were 
located physically close to praziquantel-resistant genes 
(which are not yet characterised in any Schistosoma spe-
cies). Although these microsatellites do not seem to 
serve as resistance markers, they are useful for parentage 
analysis and identifying worms that survive treatment. 
Despite no evidence for selection in this study, concerted 
drug treatment across the area for several years may have 
selected for these resistant worms over longer timescales 
and resulted in the low cure rates currently observed in 
the region more recently [24].
Interestingly, there was very little difference in genetic 
diversity between pre- and one week post-treatment. 
We expect this is because eggs were still being excreted 
from adult worms that had produced the eggs before 
treatment, but which may have then died with treat-
ment. Because genetic diversity and infection intensity 
were significantly lower at four weeks post-treatment, 
we expect most eggs of susceptible worms to be expelled 
by four weeks post-treatment. It is thought that eggs 
only survive up to three weeks after expulsion from the 
female [61]. This is supported by sibship analysis that 
finds a higher frequency of siblings between pre- and 
one week post-treatment compared to four weeks post-
treatment. It is important to note that the majority of the 
host population are still shedding viable eggs one week 
post-treatment, meaning hosts contribute to transmis-
sion even a week after successful treatment. Infection 
intensities one week post-treatment in some schools and 
some timepoints were not significantly different from 
pre-treatment infection intensities, further emphasizing 
the potentially significant contribution to transmission in 
these communities.
There was no strong evidence for effects of praziqu-
antel on genetic diversity over the medium-term. This is 
supported by other studies across sub-Saharan Africa [2, 
26, 30, 60, 62]. Most studies focus on periods well after 
national control programmes begin. Only one other 
study, in addition to this one, examines parasite diver-
sity and structure at the start of MDA. Norton et al. [21] 
found an initial decline six months after treatment at the 
start of MDA in Tanzania; however, a follow-up five years 
later demonstrated that parasite genetic diversity had 
recovered and even increased in these same schools [60]. 
One explanation for an initial decline in genetic diver-
sity observed in Tanzania is a higher degree of popula-
tion structure among the parasites compared to our sites. 
We did not observe genetic diversity declines after six 
months (only four weeks post-treatment), but recovery 
of genetic diversity of parasites at these Ugandan schools 
may be facilitated by higher rates of gene flow. Post-treat-
ment parasite populations are small in comparison to 
the refugia in untreated humans within the community 
and other contributing communities as well as parasites 
in snails [63, 64]. Combined, these studies emphasize 
the resilience of schistosome parasite populations to 
repeated praziquantel treatments.
Many studies, including ours, find that the majority of 
the genetic diversity in S. mansoni occurs at the human 
host level, rather than village or district level [21, 28, 29, 
31, 33]. This can be explained by a limited number of 
shared water contact sites and/or cercariae dispersing 
far enough to cover these sites. Genetic diversity was not 
significantly different between villages, suggesting similar 
exposure environments (all are along Lake Victoria) and 
further supporting a panmictic parasite population across 
the area surveyed. We also observed high levels of genetic 
diversity, similar to other studies that examined S. man-
soni populations in Uganda [31, 65], and higher than that 
reported from other localities in East Africa. For example, 
a study focusing on four villages in Ethiopia [66] reported 
a total of six and 15 alleles for the SMD28 and SMDA28 
loci, while in this study we recovered 26 and 54 alleles for 
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the two loci, respectively. Lake Victoria is likely the origin 
of S. mansoni and larger scale surveys have reported the 
area to have the highest levels of genetic diversity across 
several markers [24, 31, 65, 67]. This high genetic diver-
sity can increase chances of drug resistance developing 
and also help these populations recover from bottleneck-
ing selection [12, 13]. However, high genetic diversity can 
also reduce the likelihood of an allele fixing in a popula-
tion and can prevent resistance from spreading.
We found that infrapopulation genetic diversity is 
also significantly related to host age and sex. We inter-
pret infrapopulation genetic diversity as the combined 
outcome of the genetic diversity of parasites circulating 
in the environment, variation in behaviour (particularly 
those related to water contact, i.e. location, duration and 
time of day), and establishment probability (dependent 
on host susceptibility and immune history and parasite 
infectiousness). We found that males had higher para-
site genetic diversity than females. We expect this higher 
genetic diversity, particularly at younger ages, to reflect 
a difference in behaviour as young males have reported 
to play in the water more often than females of a similar 
age [68]. This effect of sex was dependent on age; males 
had similar genetic diversity across all ages surveyed here 
whereas each additional year significantly increased the 
genetic diversity of parasites observed in females. Older 
females (i.e. 10 years-old and above) help more in house-
hold chores like clothes washing and fetching water [68], 
which would increase their exposure to schistosomes 
and likely increase the genetic diversity observed in an 
infrapopulation. A study of S. haematobium in Mali also 
found significant impacts of host demographics; males 
had more unique genotypes and these private alleles 
increased with age [69]. Neither study, however, observed 
any decline in genetic diversity with age, as may be 
expected if immunity was developing. It may be that the 
genetic diversity is very high in these settings and new 
genotypes are constantly being encountered which hosts 
have not yet acquired immunity against. An alternative, 
non-exclusive, explanation is that the ages sampled here 
(6–14 years) are insufficient to detect this effect of an 
immune response on genetic diversity.
Conclusions
This study highlights the resilience of schistosome popu-
lations to repeated drug treatments in a high endemicity 
setting in Uganda. We found evidence for adult worms 
surviving treatment at the beginning of the national 
control programme, suggesting natural variation in 
resistance/tolerance. These may have been selected 
on with subsequent round of MDA and led to low cure 
rates observed a decade later. In settings with similar 
epidemiology and genetic diversity as observed here, 
MDA alone is unlikely to be sufficient for elimination and 
could even lead to long-term issues if drug resistance is 
selected.
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